This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
Achillion (ACHN) Shares Down as J&J Announces Stake Sale
by Zacks Equity Research
Achillion's (ACHN) shares fell following the announcement that J&J will sell its complete stake in the company.
Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus
by Zacks Equity Research
Achillion Pharmaceuticals' (ACHN) third-quarter loss was narrower than estimates. The company is focusing on expanding its key pipeline candidate in several indications.
3 ETFs to Watch on Biotech Earnings
by Zacks Equity Research
Major Biotech companies report mixed Q3 results.
Alexion (ALXN) Tops Q3 Earnings, Lags Sales, 2017 View Up
by Zacks Equity Research
Alexion Pharmaceuticals, Inc.???s (ALXN) beat earnings estimates but missed sales estimates in the third quarter of 2017.
Alexion (ALXN) Tops Q3 Earnings, Sales Miss, Shares Up
by Zacks Equity Research
Alexion surpassed earnings expectations but missed sales estimates in the third quarter of 2017.
Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod
by Arpita Dutt
Key highlights include Biogen's (BIIB) Q3 results and regulatory news from companies like Gilead and Alexion.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Alexion's (ALXN) blockbuster drug, Soliris, continues to perform well and the company is scheduled to report third-quarter 2017 results on Oct 26, before the opening bell.
Is the Options Market Predicting a Spike in Alexion Pharmaceuticals (ALXN) Stock?
by Zacks Equity Research
Surging implied volatility makes Alexion Pharmaceuticals (ALXN) Stock lucrative to the option traders.
What's in Store for BioMarin (BMRN) This Earnings Season?
by Zacks Equity Research
BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q3. However, slowdown in Federal purchasing orders in Brazil will hurt Naglazyme and Vimizim product revenues.
What's in the Cards for Amgen (AMGN) this Earnings Season?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug
by Arpita Dutt
Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.
The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO
3 Biotech and Pharma Stocks with Key FDA Catalysts this October
by Arpita Dutt
Here is a look at three biotech and pharma stocks including Flexion (FLXN) that have an important regulatory event lined up this month.
Mallinckrodt (MNK) Closes InfaCare Pharmaceutical Buyout
by Zacks Equity Research
Mallinckrodt (MNK) acquires privately-held InfaCare Pharmaceutical Corporation to diversify portfolio.
Intercept (ICPT) Provides Safety Guidelines For Ocaliva
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) provided a statement on the recent safety and dosing issues for lead drug Ocaliva and reinforced that the recommended dosing is safe.
Infinity/ Bristol-Myers Adds TNBC Patients to Clinical Deal
by Zacks Equity Research
Infinity (INFI) expanded its existing clinical collaboration with Bristol-Myers Squibb for evaluating IPI-549 in combination with Opdivo to include patients with triple negative breast cancer.
Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer
by Zacks Equity Research
AbbVie (ABBV) and Bristol-Myers Squibb entered into a deal to evaluate the combination of ABBV-399 and Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer.
The Medicines Co. Continues to Focus on Pipeline Development
by Zacks Equity Research
The Medicines Co.'s (MDCO) divestment of non-core assets should allow the company to focus on key assets and brings in a non-dilutive source of funds as well.
Bayer (BAYRY) Focuses on Pipeline Development & Acquisitions
by Zacks Equity Research
Bayer (BAYRY) remains focused on developing its pipeline and acquisitions in order to boost its portfolio.
Dr. Reddy's Laboratories (RDY) Surges: Stock Moves 5.7% Higher
by Zacks Equity Research
Dr. Reddy's Laboratories (RDY) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes.
Werner Enterprises, Cott, Akari Therapeutics, and Alexion highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Werner Enterprises, Cott, Akari Therapeutics, and Alexion highlighted as Zacks Bull and Bear of the Day
Akari Therapeutics (AKTX) Stock is Skyrocketing Over 60% Today: Here's Why
by Madeleine Johnson
On Thursday, shares of biopharmaceutical company Akari Therapeutics (AKTX) are skyrocketing, up over 60% in midday trading--the stock was up 90% in premarket trading--after it announced it would advance its lead drug candidate.
Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up
by Zacks Equity Research
Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.
Karyopharm's Liposarcoma Candidate Superior in Phase II Study
by Zacks Equity Research
Karyopharm's (KPTI) selinexor reduced the risk of progression or death in previously treated patients with advanced dedifferentiated liposarcoma.
Alnylam Pharmaceuticals (ALNY) Soars: Stock Adds 51.7% in Session
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) saw a big move last session, as its shares jumped nearly 52% on the day, amid huge volumes.